Journal Article

Blinded In Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades de Pointes Risk Assessment

Vargas, Hugo M., Passini, Elisa, Rodriguez, Blanca, Qu, Yusheng, Zhou, Xin, Liu, Yang, Bueno-Orovio, Alfonso

2020

Overview

Torsades de Pointes (TdP) is a type of ventricular arrhythmia which could be observed as an unwanted drug-induced cardiac side effect, and it is associated with repolarization abnormalities in single cells. The pharmacological evaluations of TdP risk in previous years mainly focused on the hERG channel due to its vital role in the repolarization of cardiomyocytes. However, only considering drug effects on hERG led to false positive predictions since the drug action on other ion channels can also have crucial regulatory effects on repolarization. To address the limitation of only evaluating hERG, the Comprehensive in Vitro Proarrhythmia Assay initiative has proposed to systematically integrate drug effects on multiple ion channels into drug trial to improve TdP risk assessment. It is not clear how many ion channels are sufficient for reliable TdP risk predictions, and whether differences in IC and Hill coefficient values from independent sources can lead to divergent prediction outcomes. The rationale of this work is to investigate the above two questions using a computationally efficient population of human ventricular cells optimized to favor repolarization abnormality. Our blinded results based on two independent data sources confirm that simulations with the optimized population of human ventricular cell models enable efficient in silico drug screening, and also provide direct observation and mechanistic analysis of repolarization abnormality. Our results show that 1) the minimum set of ion channels required for reliable TdP risk predictions are Nav1.5 (peak), Cav1.2, and hERG; 2) for drugs with multiple ion channel blockage effects, moderate IC variations combined with variable Hill coefficients can affect the accuracy of predictions.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Accuracy / Arrhythmia / Calcium channels (voltage-gated) / Cardiac arrhythmia / Cardiomyocytes / Cell culture / Datasets / drug cardiotoxicity / Drug development / Drug screening / HERG protein / human ventricular action potential / in silico drug trials / Ion channels / Machine learning / Ordinary differential equations / Pharmaceutical industry / Pharmacology / Potassium / Potassium channels (voltage-gated) / Predictions / Regression analysis / Risk assessment / Simulation / Sodium / Sodium channels (voltage-gated) / Software / Torsades de Pointes / Ventricle